Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Cantargia
1,63
SEK
−0,73 %
1 295 seuraajaa
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Yleiskuva
Omistajat
Sijoittajakonsensus
−0,73%
+9,4%
−10,68%
−3,55%
−45,38%
−52,48%
−85,58%
−88,34%
−76,94%
Cantargia operates in the pharmaceutical industry and focuses on the development of treatments for cancer and inflammatory diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Cantargia was founded in 2009 and is headquartered in Lund, Sweden.
Lue lisääMarkkina-arvo
405,24 milj. SEK
Vaihto
323,2 t. SEK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Pörssikalenteri
13.5.
2025
Osavuosikatsaus Q1'25
15.5.
2025
Yhtiökokous '25
21.8.
2025
Osavuosikatsaus Q2'25
Kaikki
Webcastit
Tiedotteet
Kolmansien osapuolien sisällöt
NäytäKaikki sisältötyypit
Cantargia announces selection of treatment resistant atopic dermatitis as second target indication for CAN10
Cantargia announces the publication of preclinical data highlighting nadunolimab's potential to counteract tumor-driven systemic immunosuppression
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Cantargia presents association between nadunolimab and reduction of chemotherapy induced peripheral neuropathy (CIPN) at AACR
Cantargia presents promising preclinical results on anti-IL1RAP antibody-drug conjugate (ADC) at a major cancer conference
Cantargia, Audiocast with teleconference, Q1'25
Cantargia publishes Annual Report 2024
Notice of annual general meeting in Cantargia AB (publ)
Cantargia appoints Morten Lind Jensen as Chief Medical Officer
Cantargia publishes an abstract on parallel anti-tumor activity and reduction of chemotherapy-induced neuropathy with nadunolimab
Cantargia presents promising preclinical results on a novel IL1RAP-targeting antibody-drug conjugate at AACR 2025.
Cantargia to Participate at Van Lanschot Kempen’s Life Sciences Conference
First patient enrolled in Cantargia’s leukemia study with nadunolimab
Cantargia’s TRIFOUR phase 2 study investigating nadunolimab in triple negative breast cancer fully recruited
Cantargia to Participate at H.C. Wainwright’s Annual Autoimmune & Inflammatory Virtual Conference
Cantargia reports promising CAN10 phase 1 data from first multiple dose cohort, and FDA and Key Opinion Leader feedback
Redeye: Cantargia Q4 2024 - Focus on Business Development
